Search

Minnesota Rep. Jim Hagedorn has died after a long battle with kidney cancer, his wife announced Friday on Facebook. "Today, I join my colleagues on the House Agriculture Committee and full House of Representatives in mourning the devastating loss of Rep. Jim Hagedorn", House Agriculture Committee Republican Leader Glenn "GT" Thompson said in a statement. [Extracted from the article]

The article discusses the phase III clinical study of Genentech's drug Avastin. It is stated that Avastin, in combination with interferon alfa-2a therapy, increased the progression-free survival of patients with first-line metastatic renal cell carcinoma. The primary analysis of the study is to assess improvement in progression-free survival (PFS) which is defined as the length of time the tumor did not grow or patient death did not occur.

Reports on the results of the recent phase II trial of Bayer AG's anticancer drug, BAY 43-9006. Percentage of kidney cancer patients who showed either tumor shrinkage or disease stabilization after administration of BAY 43-9006; Adverse events experienced by cancer patients; Description on how BAY 43-9006 works.

Focuses on recent developments related to kidney cancer. Decision by Exelixis Inc. to move two anticancer compounds and one diabetic kidney disease drug into phase II trials; Notification received by British biopharmaceutical firm Antisoma PLC from the U.S. Food and Drug Administration, that its drug AS1411 has been granted orphan drug designation in the U.S. for the treatment of renal cancer; Commencement by Spectrum Pharmaceuticals Inc. of a new phase II study of its investigational anticancer drug EOquin in patients with high-risk superficial bladder cancer.

Sunitinib is an oral multi-kinase inhibitor, works by blocking several enzymes that promote cell growth [ABSTRACT FROM AUTHOR]

Sunitinib is an oral multi-kinase inhibitor, works by blocking several enzymes that promote cell growth [ABSTRACT FROM AUTHOR]

Glenmark Pharmaceuticals has informed that it has attached media release on 16th February 2021 titled 'Glenmark launches SUTIB (Sunitinib)-priced 96% lower than the innovator brand. Reduces the risk of kidney cancer progression by 58%' which is self-explanatory. [Extracted from the article]

The article reports on drugs which the halt progress of metastatic kidney cancer, including Sutent from Pfizer, and Panzem from EntreMed. In phase III of a research, sunitinib,marketed as Sutent by Pfizer, was shown to be more efficient in halting the progress of the disease. EntreMed also began a phase II trial to evaluate the safety and efficacy of Panzem, alone and in combination with Sutent in patients with kidney cancer.

The article offers world news briefs related to the development of drugs for kidney cancer treatment. The drug Sutent from Pfizer Inc. has been approved by the Food and Drug Administration (FDA) for the addition of data to its labeling, which supports its use as a first-line treatment of advanced kidney cancer. Sutent has also received the European Commission marketing authorization for kidney cancer treatment, which makes it as the first inhibitor of its kind to be approved in Europe.

The article presents information on new developments related to kidney cancer. Cancer drug developer Antisoma PLC will enroll renal cancer and melanoma patients in the clinical trial for its new drug, AS1409. Another clinical trial conducted by Antisoma shows that its renal cancer drug AS1411 helped in reducing the size of tumor. Argos Therapeutics has been conducting a clinical trial to test the efficacy of AGS-003, a personalized immunotherapy for advanced kidney cancer.

The article reports global developments related to kidney and bladder cancer. Pfizer Inc.'s Sutent has received European conditional marketing authorizations in advanced kidney cancer and gastrointestinal stromal tumor. The European Commission has approved marketing authorization to Bayer Corp. and Onyx Corp.'s Nexavar tablets for the treatment of patients with kidney cancer. Cell Genesys Inc. will undergo a phase I clinical trial of its CG0070 drug in patients with bladder cancer.

Discusses a study initiated by Novogen subsidiary, Marshall Edwards, to examine the ability of its investigational anti-cancer drug, phenoxodiol, to enhance the effect of platinum drugs in patients with solid cancers, particularly cancer of the kidney. Important aspects of the study being conducted at Saint George Hospital in Sydney, New South Wales; Determination of the appropriate dose level of phenoxodiol for renal cancer.

The article presents information on the U.S. Food & Drug Administration's (FDA) approval of a kidney cancer drug developed by GlaxoSmithKline. The drug helps treat patients with advanced renal cell carcinoma (RCC). The company mentions that the drug prevents the growth of new blood vessels and thus blocking the growth of the kidney cancer tumors. Paolo Paoletti senior vice-president of GlaxoSmithKline mentions the drug will provide patients with new oral treatment options.

The article focuses on the issues concerning the efficiency of Oncophage in treating early-stage renal cell carcinoma in Europe. It cites an opinion raised by the European Medicines Evaluation Agency (EMEA), informing that Antigenics Inc., the developer of the drug, should anticipate a negative opinion on the Marketing Authorization Application for Oncophage. It notes that the negative opinion means that the marketing application of the product is more likely to fail.

The article reports on the approval of Nexavar drug from Bayer and Onyx Pharmaceuticals to treat renal cell carcinoma in Japan. The approval makes Nexavar the first oral targeted therapy to be granted in the pharmaceutical market. It will advance the outcomes of patients affected with renal cell carcinoma (RCC). The drug is based on results from a randomized Phase III trial of more than 900 metastatic RCC patients, which showed that the drug slowed tumor progression.

The article reports that Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals Inc.'s Nexavar has been approved for use in metastatic renal cell carcinoma (RCC) patients in Japan. The approval was based on the results from the Phase III trial, which found that Nexavar can slow tumor progression within 24 weeks. Moreover, the drug is the first oral targeted therapy to be approved in the country.

The article reports on the revelation of U.S.-based Antigenics Inc. in its end-of-study results of therapeutic cancer vaccine Oncophage. According to biotechnology firm, its end-of-study results have shown that Oncophage prolongs recurrence-free survival of about 45% in patients with intermediate-risk kidney cancer.

The article reports developments related to the treatment of kidney cancer. The U.S. Food and Drug Administration has granted priority review for the investigational treatment of Wyeth's Torisel for use in kidney cancer. A report has been published by Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals Inc. regarding a phase II trial demonstrating that the drugs Nexavar and Sutent can slow down the progression of kidney cancer.

This article reports that Pfizer Inc. has been trying to get permission for expanding the approved indications for Sutent to include newly diagnosed kidney cancer patients in Europe. The drug has been recently approved as a second line treatment in renal cell carcinoma. The new application will increase the pressure on Bayer and Onyx Pharmaceuticals' Nexavar, Sutent's competitor in the kidney cancer market.

The article presents several articles about cancer including "Pipeline Insight: Breast Cancer - A diverse and increasingly crowded pipeline," "Pipeline Insight: Cancer Overview - Emerging therapeutic and commercial opportunities," and "Stakeholder Opinions: Renal Cell Carcinoma Novel targeted therapies to fill the void."

The article presents a list of reports related to cancer including "Stakeholder Opinions: Renal Cell Carcinoma Novel Targeted Therapies to Fill the Void," "Generic Cancer Market: New Legislation and a Wave of Patient Expiries to Transform the Market," and "The Asian Cancer Market Outlook to 2010."

This article reports that Bayer AG and Onyx Corp. have submitted a new drug application to the U.S. Food and Drug Administration for sorafenib in patients with advanced renal cell carcinoma (RCC) following positive phase III trial results. Given the current dearth in pharmacotherapy for patients with renal cell carcinoma, sorafenib, if approved, is likely to become the gold standard for this indication, with sales of $400 million forecast for 2012. In the U.S., RCC accounts for approximately 3% of adult malignancies and 90-95% of tumors arising from the kidney. Five-year survival for patients with localized RCC is approximately 40%, but for those patients with advanced RCC, the outlook is poor and five-year survival is approximately 11%.

Reports that Bayer AG and Onyx Pharmaceuticals Inc. have announced positive study data for the Bay 43-9006 drug in the treatment of kidney cancer. Evidence of antitumor activity; Goal of obtaining approval for the drug; Observations noted from patients enrolled in the study.

Presents news headlines for February 15-March 14, 2004, concerning cancer research and cancer treatment industry. Marshall Edwards' clinical trial in cervical cancer; Orphan drug designation received by CuraGen from the U.S. Food and Drug Administration for compound targeting oral mucositis; Human kidney cancer trial launched by Novogen subsidiary.

Reports on the cessation for the development of Neovastat that is indicated to treat renal cell carcinoma by AEterna Laboratories Inc. in Quebec City. Impact of the disease on reducing the percentage of the workforce; Observations found in patients receiving the kidney cancer drug; Factors contributing the discontinuance of the phase trial.

Reports that the United States Food and Drug Administration (FDA) has placed a partial clinical hold on the phase III trials of Antigenics' Oncophage under its investigational new drug application, which included trials in kidney cancer and metastatic melanoma. Impact on Antigenics' share price; Main priority of the FDA.